NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 30.52% | -1.78% | -13.91% | -86.75% | -36.16% |
| Total Depreciation and Amortization | 15,933.33% | 6,040.00% | 2,760.00% | 780.00% | -40.00% |
| Total Amortization of Deferred Charges | -100.00% | -100.00% | -60.94% | 39.16% | -- |
| Total Other Non-Cash Items | -79.17% | -19.59% | 51.96% | 7,563.27% | 838.90% |
| Change in Net Operating Assets | -112.70% | -42.08% | -73.37% | -100.45% | -106.52% |
| Cash from Operations | -66.00% | -42.90% | -32.67% | -6.53% | 14.85% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -256,200.00% | -- |
| Total Debt Issued | -98.11% | -26.16% | -26.16% | 202.29% | 7,881.53% |
| Total Debt Repaid | 97.01% | 96.62% | 93.61% | 31.35% | -11.67% |
| Issuance of Common Stock | 217.78% | -46.51% | 144.76% | 144.76% | 48.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 443.81% | 374.38% | 197.36% | 285.70% | -- |
| Cash from Financing | 265.65% | 30.26% | 210.97% | 360.35% | 1,306.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,249.41% | -72.45% | 301.59% | 176.32% | 107.74% |